These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
839 related articles for article (PubMed ID: 28198398)
1. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398 [TBL] [Abstract][Full Text] [Related]
2. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma. Ma L; Fan Z; Du G; Wang H Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935 [TBL] [Abstract][Full Text] [Related]
3. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC. Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727 [TBL] [Abstract][Full Text] [Related]
4. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125 [TBL] [Abstract][Full Text] [Related]
5. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism. Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382 [TBL] [Abstract][Full Text] [Related]
6. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma. Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701 [TBL] [Abstract][Full Text] [Related]
7. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance. Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539 [TBL] [Abstract][Full Text] [Related]
9. PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation. Ma J; Weng L; Jia Y; Liu B; Wu S; Xue L; Yin X; Mao A; Wang Z; Shang M J Cell Mol Med; 2020 Mar; 24(5):2917-2930. PubMed ID: 31989778 [TBL] [Abstract][Full Text] [Related]
10. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840 [TBL] [Abstract][Full Text] [Related]
11. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Xiong G; Huang H; Feng M; Yang G; Zheng S; You L; Zheng L; Hu Y; Zhang T; Zhao Y J Exp Clin Cancer Res; 2018 Apr; 37(1):76. PubMed ID: 29615098 [TBL] [Abstract][Full Text] [Related]
12. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells. Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329 [TBL] [Abstract][Full Text] [Related]
13. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261 [TBL] [Abstract][Full Text] [Related]
14. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer. Zhang X; Zhao P; Wang C; Xin B Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma. Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261 [TBL] [Abstract][Full Text] [Related]
16. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis. Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243 [TBL] [Abstract][Full Text] [Related]
17. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003 [TBL] [Abstract][Full Text] [Related]
18. ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis. Mao X; Xu J; Xiao M; Liang C; Hua J; Liu J; Wang W; Yu X; Meng Q; Shi S Redox Biol; 2024 Jul; 73():103200. PubMed ID: 38781729 [TBL] [Abstract][Full Text] [Related]
19. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Pan CH; Otsuka Y; Sridharan B; Woo M; Leiton CV; Babu S; Torrente Gonçalves M; Kawalerski RR; K Bai JD; Chang DK; Biankin AV; Scampavia L; Spicer T; Escobar-Hoyos LF; Shroyer KR Mol Oncol; 2020 Aug; 14(8):1800-1816. PubMed ID: 32533886 [TBL] [Abstract][Full Text] [Related]
20. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]